Stock listing

OTC:MATPF MaaT Pharma Stock

US listing (OTC) of MaaT Pharma · home listing Euronext:MAAT

Follow MaaT Pharma into a list and get an email when it puts out news.

Home listing price · EURONEXT:MAAT

€0.78 EUR -0.12 (-13.3%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, EURONEXT:MAAT

Past year -81.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
€0.762 – €0.87 EURNov 20, 2026
Volume
101,572 sharesNov 20, 2026
Market cap
€14.68M EURAt the close on Nov 20, 2026 · price × 18.82M shares outstanding
52-week range
€0.762 – €8.62 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
€146,383 EURMedian day 55,218 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
MaaT Pharma logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Euronext:MAAT · Home€0.78 EUR-0.12 (-13.3%)101,572€0.87€0.87€0.762€0.90Close on Nov 20, 2026
Frankfurt:4RD€0.742 EUR-0.098 (-11.7%)—€0.823€0.823€0.742€0.840Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · EURONEXT:MAAT · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€0.78-0.12-13.3%€0.87€0.87€0.762101,572
€0.90-0.102-10.2%€1.00€1.00€0.90178,357
€1.002-0.024-2.3%€1.03€1.036€1.00227,171
€1.026-0.002-0.2%€1.03€1.056€1.02647,611
€1.028-0.032-3.0%€1.08€1.082€1.02454,922
€1.06-0.01-0.9%€1.10€1.10€1.05258,651
€1.07-0.022-2.0%€1.092€1.10€1.06837,033
€1.092-0.002-0.2%€1.148€1.148€1.09246,093
€1.094+0.004+0.4%€1.09€1.198€1.078125,572
€1.09+0.09+9.0%€1.064€1.27€1.02340,355
€1.00-0.016-1.6%€1.016€1.04€1.0042,804
€1.0160.000.0%€1.016€1.038€1.01424,874
€1.016-0.014-1.4%€1.05€1.05€1.01231,931
€1.03+0.012+1.2%€1.02€1.04€1.0124,531
€1.018-0.052-4.9%€1.092€1.122€1.01689,787
€1.07+0.028+2.7%€1.042€1.09€1.0371,712
€1.042-0.002-0.2%€1.042€1.052€1.01884,368
€1.044-0.018-1.7%€1.07€1.07€1.03842,221
€1.062-0.006-0.6%€1.08€1.09€1.03831,788
€1.068+0.006+0.6%€1.12€1.12€1.05837,054
€1.062-0.034-3.1%€1.14€1.14€1.03855,514
€1.096+0.076+7.5%€1.05€1.19€1.014198,814
€1.02+0.02+2.0%€1.25€1.30€1.02490,141
€1.00+0.01+1.0%€0.99€1.026€0.98257,407
€0.99+0.016+1.6%€0.97€0.99€0.96122,578
€0.974+0.033+3.5%€0.951€0.974€0.9323,905
€0.941+0.028+3.1%€0.94€0.951€0.90830,902
€0.913+0.005+0.6%€0.93€0.93€0.91211,589
€0.908-0.014-1.5%€0.906€0.92€0.90339,248
€0.922-0.008-0.9%€0.95€0.95€0.90422,293
€0.93-0.053-5.4%€0.96€0.979€0.9319,570
€0.983-0.007-0.7%€0.99€0.991€0.9561,084
€0.99+0.051+5.4%€0.982€1.01€0.92569,515
€0.939-0.071-7.0%€1.01€1.014€0.916195,649
€1.01-0.02-1.9%€1.032€1.08€1.00154,897
€1.03-0.054-5.0%€1.09€1.186€1.01112,846
€1.084-0.046-4.1%€1.11€1.13€1.08292,618
€1.13-0.01-0.9%€1.25€1.25€1.1373,643
€1.14+0.006+0.5%€1.27€1.28€1.14156,328
€1.134-0.128-10.1%€1.296€1.296€1.134137,369
€1.262-0.096-7.1%€1.39€1.39€1.252120,579
€1.358-0.072-5.0%€1.388€1.418€1.312130,781
€1.43+0.13+10.0%€1.368€1.59€1.33353,541
€1.30-0.33-20.2%€1.63€1.66€1.30315,707
€1.63-0.37-18.5%€2.02€2.22€1.63417,364
€2.00+0.56+38.9%€1.44€2.00€1.44422,021
€1.44+0.36+33.3%€1.108€1.47€1.108410,459
€1.08-1.435-57.1%€1.06€1.16€1.00444,282
€2.515-0.22-8.0%€2.68€2.68€2.5179,774
€2.735-0.055-2.0%€2.78€2.88€2.7033,087
€2.79+0.135+5.1%€2.66€2.835€2.6638,283
€2.655-0.145-5.2%€2.75€2.785€2.6534,428
€2.80-0.08-2.8%€2.89€2.895€2.7835,012
€2.88-0.06-2.0%€2.96€2.96€2.8028,531
€2.94+0.005+0.2%€3.045€3.045€2.9425,902
€2.935-0.025-0.8%€2.96€2.965€2.9213,621
€2.96-0.045-1.5%€2.97€3.00€2.967,517
€3.005+0.045+1.5%€3.00€3.075€2.96527,930
€2.96-0.065-2.1%€3.03€3.03€2.9224,554
€3.025+0.005+0.2%€3.03€3.075€2.9628,125
€3.02+0.03+1.0%€3.00€3.07€2.9422,385
€2.99-0.05-1.6%€3.05€3.06€2.9823,536
€3.04-0.005-0.2%€3.06€3.09€2.9832,349
€3.045-0.145-4.5%€3.28€3.28€2.95580,235
€3.19+0.07+2.2%€3.12€3.40€3.05131,751
€3.12-0.03-1.0%€3.26€3.38€3.06577,249
Ticker
OTC:MATPF
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

What changed lately

Latest news

All MaaT Pharma news

MaaT Pharma on 6ix

Sector
Health care
Industry
Biotechnology
News releases
23 in the last 12 months · 41 in all · newest Nov 16, 2026 · oldest 2025
Decks
27 decks · latest October 2026

Where MaaT Pharma is listed

ListingExchangeCountryCurrency
Euronext:MAAT · Home listingEuronextFranceEUR
gettex:4RDgettexGermanyEUR
LS Exchange:A3C7A5LS ExchangeGermanyEUR
Lang & Schwarz:A3C7A5Lang & SchwarzGermanyEUR
Frankfurt:4RDFrankfurtGermanyEUR
OTC:MATPF · This pageOTCUnited StatesUSD
Hamburg:4RDHamburgGermanyEUR
Munich:4RDMunichGermanyEUR
Stuttgart:4RDStuttgartGermanyEUR
Dusseldorf:4RDDusseldorfGermanyEUR

Valuation

EV/sales 4.7× against a median of 2.7×: 3rd lowest of 4 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
€21.29M EUR
P/E
Loss
EV/sales
4.7×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
30.7%
Operating margin
−754.9%
Net margin
−686.6%
Debt to equity
Negative equity
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
MaaT Pharma · EURONEXT:MAATUS$16.11MUS$23.36Mn/a4.7×n/an/a−686.6%n/an/a
SynCore Biotechnology Co., Ltd. · TPEX:4192US$16.80MUS$12.38Mn/a15.6×n/a2.5×−178.5%0.0×n/a
Initiator Pharma A/S · OMXSTO:INITUS$16.74MUS$15.65Mn/an/an/a13.4×n/a1.1×n/a
Neurotech International Ltd. · ASX:NTIUS$16.63MUS$15.06Mn/an/an/a41.1×n/a0.0×n/a
Akari Therapeutics PLC · NASDAQ:AKTXUS$16.41MUS$10.66Mn/an/an/a0.9×n/a0.0×1.49
Lipocine Inc. · NASDAQ:LPCNUS$16.39M−US$5.07Mn/a−1.4×n/a0.8×−249.2%0.0×1.18
Elicera Therapeutics AB · OMXSTO:ELICUS$16.09MUS$10.40Mn/an/an/a2.9×n/a0.0×n/a
Pasithea Therapeutics Corp. · NASDAQ:KTTAUS$16.00M−US$25.22Mn/an/a−0.1×0.4×n/a0.0×0.97
Atossa Therapeutics, Inc. · NASDAQ:ATOSUS$15.92M−US$4.66Mn/an/an/a0.7×n/a0.0×0.87
Quoin Pharmaceuticals. Ltd · NASDAQ:QNRXUS$15.76M−US$17.43Mn/an/an/a0.6×n/a0.0×0.68
Celularity Inc. · NASDAQ:CELUUS$15.02MUS$50.46Mn/a2.7×n/an/a−117.3%n/a1.47
Median of the othersUS$16.24MUS$10.53M2.7×−0.1×0.9×−178.5%0.0×1.08

Forecasts

Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.

Price target
3.00 EUR · Analysts' mean
EPS, year to Dec 2026
-2.12 · 3 analysts
Revenue, year to Dec 2026
5.78M · 3 analysts

Team and board

Officers

OfficerRole
Hervé AffagardCEO and co-founder
Eric SoyerChief Financial Officer
Guilhaume DEBROASMaaT Pharma – Investor Relations

Board

DirectorRole
Jean-Marie LefevreChairman of the Board – Non-Executive Director
Claude BertrandIndependent director
Hervé AffagardCEO and co-founder
Isabelle de CrémouxNon-Executive Director
Jean VolatierIndependent director
Muriel PrudentNon-Executive Director
Nadia KamalIndependent director

Events

QuarterResultsShare move
Q4 2025Mar 30, 2026−16.0%
Quarter to Sep 30, 2025Nov 4, 2025−1.4%
Q2 2025Sep 17, 2025−4.7%
Quarter to Mar 31, 2025Apr 14, 2025+5.1%
Q4 2024Mar 27, 20250.0%
Quarter to Sep 30, 2024Nov 5, 2024+1.9%
Q2 2024Sep 19, 2024+2.8%
Q1 2024Apr 2, 2024 · After close+0.5%
Q4 2023Mar 28, 2024−5.0%
Q3 2023Nov 9, 2023 · After close−2.4%
All 17 quarters
QuarterResultsShare move
Q2 2023Jul 27, 2023 · After close−3.1%
Q1 2023May 9, 2023 · After close−3.7%
Q4 2022Mar 30, 2023+3.1%
Q3 2022Nov 8, 2022 · After close−1.1%
Q2 2022Jul 28, 2022 · After close+1.0%
Q1 2022Apr 14, 2022 · Before open0.0%
Q3 2021Oct 20, 2021 · Before open

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck27 slidesOctober 2026
Investor Presentation (September 2026)Investor deck28 slidesSeptember 2026
Investor Presentation (July 2026)Investor deck28 slidesJuly 2026
Shareholder Meeting (June 2026)Shareholder meeting32 slidesJun 16, 2026
Investor Presentation (March 2026)Investor deck28 slidesMarch 2026
Investor Presentation (October 2025)Investor deck31 slidesOctober 2025
Investor Presentation (April 2025)Investor deck32 slidesApril 2025
Investor Presentation (February 2025)Investor deck32 slidesFebruary 2025
Investor Presentation (January 2025)Investor deck33 slidesJanuary 2025
Technical Presentation (December 2024)Technical25 slidesDecember 2024
All 27 decks
DeckKindSlidesDate
Investor Presentation (November 2024)Investor deck22 slidesNovember 2024
Investor Presentation (October 2024)Investor deck34 slidesOctober 2024
EBMT 2024Conference20 slidesOctober 2024
Investor Presentation (May 2024)Investor deck30 slidesMay 2024
Investor Presentation (April 2024)Investor deck30 slidesApril 2024
Investor Presentation (March 2024)Investor deck31 slidesMarch 2024
Investor Presentation (January 2024)Investor deck31 slidesJanuary 2024
Investor Presentation (December 2023)Investor deck30 slidesDecember 2023
Investor Presentation (September 2023)Investor deck37 slidesSeptember 2023
Investor Presentation (July 2023)Investor deck37 slidesJuly 2023
Investor Presentation (June 2023)Investor deck37 slidesJune 2023
Investor Presentation (January 2023)Investor deck37 slidesJanuary 2023
Investor Presentation (August 2022)Investor deck32 slidesAugust 2022
Investor Day (June 2022)Investor day93 slidesJun 7, 2022
Investor Presentation (May 2022)Investor deck29 slidesMay 6, 2022
Investor Presentation (March 2022)Investor deck29 slidesMar 29, 2022
Investor Presentation (January 2022)Investor deck29 slidesJan 23, 2022

Open Decks

Financings

RaiseDateIn US dollars
Private placement of new ordinary shares
Closed: €9.1M raised · €3.48 a share · Portzamparc, BNP Paribas Group
Dealers: Portzamparc, BNP Paribas Group (lead)
Buyers: PSIM represented by Bpifrance Investissement (pledged to subscribe for €1.5 million); Biocodex (€1.5 million); Fonds PSIM (Bpifrance Investissement) (€1.5 million); Invus Public Entities (€1.5 million)
Insiders: Existing shareholders PSIM (Bpifrance Investissement) and Biocodex pledged to subscribe €1.5 million each, €3 million in total; Biocodex's president is a board member
Use of proceeds: Fund its roadmap: preparing Xervyteg commercialization, MaaT033 development, FDA discussions, working capital and general corporate purposes
Nov 14, 2025US$10.58M
Loan with warrants attached
Tranche closed: €3.5M raised · Warrants at €4.5898 for 240 months · Van Lanschot Kempen
Dealers: Van Lanschot Kempen
Buyers: European Investment Bank (EIB) (€37.5 million, 4-tranche loan with warrants attached); European Investment Bank (Tranche A loan of €3.5 million and 468,772 warrants)
Use of proceeds: Advance late-stage hemato-oncology programs, including Xervyteg and MaaT033
Nov 4, 2025US$4.02M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in EUR

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue4.52M3.22M2.23M1.43M972.0K089.3K892.0K109.3K
Cost of revenue3.13M1.25M1.44M339.0K166.0K164.0K97.0K79.0K3.50M
Gross profit1.39M1.97M784.0K1.09M806.0K-164.0K-7.70K813.0K-3.39M
Research and development27.6M27.5M20.3M14.5M9.14M6.10M5.27M4.51M
Selling, general and administrative8.22M2.66M2.35M1.47M1.17M1.29M922.0K787.0K
Operating income-34.1M-28.4M-19.9M-13.6M-8.89M-7.39M-4.96M-4.40M-4.71M
Depreciation and amortization1.74M1.69M871.0K429.0K328.0K164.0K97.0K79.0K51.2K
EBITDA-32.4M-26.7M-19.1M-13.1M-8.56M-7.22M-4.87M-4.33M-4.66M
Interest expense1.27M868.0K413.0K201.0K121.0K45.0K20.0K71.0K0
Income before tax-34.9M-32.4M-19.7M-13.7M-9.02M-6.79M-5.84M-4.47M-4.78M
Income tax-3.79M-3.52M-3.63M157.0K121.0K-1.49M803.0K71.0K-922.8K
Net income-31.1M-28.9M-19.7M-13.7M-9.02M-5.35M-6.65M-4.55M-3.86M
Earnings per share, basic-1.95-2.21-1.73-1.39-3.72-25.91-32.20-4.40-3.74

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents24.9M20.2M24.3M35.2M43.3M19.9M5.41M3.60M7.35M
Short-term investments95.0K66.0K34.0K63.0K
Receivables6.82M1.51M5.16M1.05M3.51M2.24M1.50M794.0K4.23K
Inventory84.0K64.0K190.0K47.0K33.0K-97.0K27.4K128.9K
Current assets33.0M27.6M32.0M42.1M47.3M22.2M6.98M4.73M8.79M
Property, plant and equipment7.33M8.60M9.17M966.0K1.11M1.10M428.0K391.0K313.0K
Goodwill44.1K
Total assets44.6M38.5M42.9M44.7M49.4M24.3M8.17M5.88M9.26M
Accounts payable11.8M8.83M6.35M4.51M34.0K1.40M1.68M1.42M1.14M
Current liabilities17.0M14.6M11.5M9.22M4.70M2.86M2.63M2.24M1.45M
Long-term debt11.0M7.80M5.42M7.93M3.96M4.72M9.92M2.17M
Total debt17.4M16.0M14.1M11.4M5.81M6.08M10.5M2.60M1.72M
Total liabilities42.8M28.2M22.5M17.9M9.56M8.34M12.7M4.62M3.99M
Shareholders' equity1.80M10.3M20.5M26.8M39.9M15.9M-4.57M1.27M5.27M
Shares outstanding15.9M13.1M11.4M9.89M2.43M206.5K206.5K1.03M1.03M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-15.9M-22.0M-18.7M-12.6M-7.93M-5.81M-5.02M-3.87M-3.87M
Capital spending-609.0K-753.0K-1.09M-662.0K-238.0K-316.0K-128.0K-291.0K-291.0K
Free cash flow-16.5M-22.8M-19.8M-13.3M-8.17M-6.13M-5.15M-4.16M-4.16M
Cash from investing-497.0K-416.0K-440.0K-815.0K-238.0K-523.0K-154.0K-311.0K-311.0K
Cash from financing21.1M18.3M8.14M5.36M31.6M20.8M6.98M432.0K432.0K
Share buybacks-45.0K17.3M-79.0K-137.0K32.4M18.0M028.0K
Change in cash4.71M-4.13M-11.0M-8.06M23.4M14.5M1.81M-3.75M-3.75M

Open Financials

Cap table

Built by 6ix from MaaT Pharma’s releases · as of Nov 14, 2025

Common shares
18,824,425
Fully diluted
18,824,425

Fully diluted

LineShares
Common shares18,824,425

Warrants and options

Lot
Warrants · €4.59 · expire about Nov 2045

Share count over time

CountShares
Nov 22, 202618,824,425

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Claude BertrandIndependent director · Since at least Jun 24, 2025
Eric SoyerChief Financial Officer · Since at least Oct 19, 2026
Guilhaume DEBROASMaaT Pharma – Investor Relations · Since at least Dec 8, 2025
Hervé AffagardCEO and co-founder · Since at least Oct 19, 2026
Isabelle de CrémouxNon-Executive Director · Since at least Nov 5, 2026
Jean-Marie LefevreChairman of the Board – Non-Executive Director · Since at least Jun 24, 2025
Jean VolatierIndependent director · Since at least Jun 24, 2025
Muriel PrudentNon-Executive Director · Since at least Nov 5, 2026
Nadia KamalIndependent director · Since at least Jun 24, 2025

Open People

Log in to ask 6ix AI your own questions about MaaT Pharma.